Your browser doesn't support javascript.
loading
The PrU: Development and validation of a measure to assess personal utility of genomic results.
Turbitt, Erin; Kohler, Jennefer N; Angelo, Frank; Miller, Ilana M; Lewis, Katie L; Goddard, Katrina A B; Wilfond, Benjamin S; Biesecker, Barbara B; Leo, Michael C.
Afiliación
  • Turbitt E; Graduate School of Health, University of Technology Sydney, Ultimo, New South Wales, Australia. Electronic address: erin.turbitt@uts.edu.au.
  • Kohler JN; Stanford Center for Undiagnosed Diseases, Standard University, Stanford, CA.
  • Angelo F; Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL.
  • Miller IM; Rare Disease Institute, Children's National Hospital, Washington, DC.
  • Lewis KL; National Human Genome Research Institute, National Institutes of Health, Bethesda, MD.
  • Goddard KAB; Center for Health Research, Kaiser Permanente Northwest, Portland, OR.
  • Wilfond BS; Treuman Katz Center for Pediatric Bioethics, Seattle Children's Hospital, Seattle, WA.
  • Biesecker BB; Genomics, Ethics, and Translational Research Program, RTI International, Washington, DC.
  • Leo MC; Center for Health Research, Kaiser Permanente Northwest, Portland, OR.
Genet Med ; 25(3): 100356, 2023 03.
Article en En | MEDLINE | ID: mdl-36516964
ABSTRACT

PURPOSE:

People report experiencing value from learning genomic results even in the absence of clinically actionable information. Such personal utility has emerged as a key concept in genomic medicine. The lack of a validated patient-reported outcome measure of personal utility has impeded the ability to assess this concept among those receiving genomic results and evaluate the patient-perceived value of genomics. We aimed to construct and psychometrically evaluate a scale to measure personal utility of genomic results-the Personal Utility (PrU) scale.

METHODS:

We used an evidence-based, operational definition of personal utility, with data from a systematic literature review and Delphi survey to build a novel scale. After piloting with 24 adults, the PrU was administered to healthy adults in a Clinical Sequencing Evidence-Generating Research Consortium study after receiving results. We investigated the responses using exploratory factor analysis.

RESULTS:

The exploratory factor analysis (N = 841 participants) resulted in a 3-factor solution, accounting for 74% of the variance in items (1) self-knowledge (α = 0.92), (2) reproductive planning (α = 0.89), and (3) practical benefits (α = 0.91).

CONCLUSION:

Our findings support the use of the 3-factor PrU to assess personal utility of genomic results. Validation of the PrU in other samples will be important for more wide-spread application.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Genómica Tipo de estudio: Systematic_reviews Límite: Adult / Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2023 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Genómica Tipo de estudio: Systematic_reviews Límite: Adult / Humans Idioma: En Revista: Genet Med Asunto de la revista: GENETICA MEDICA Año: 2023 Tipo del documento: Article